Study on Bill S-209, An Act respecting Pandemic Observance Day
https://policybase.cma.ca/link/policy14467

POLICY TYPE
Parliamentary submission

DATE
2022-02-09

TOPICS
Health care and patient safety
Ethics and medical professionalism

Documents

Appearance before the Senate Standing Committee on Social Affairs, Science and Technology

Study on Bill S-209, An Act respecting Pandemic Observance Day

Dr. J. Alainercourt
President of the Canadian Medical Association

February 09, 2022
(Clarification details)
CMA Submission to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities’ study of Bill C-3, An Act to amend the Criminal Code and the Canada Labour Code

https://policybase.cma.ca/link/policy14464

POLICY TYPE  Parliamentary submission
DATE  2021-12-15
TOPICS  Health care and patient safety, Ethics and medical professionalism

Documents
Vaccine acceptance

https://policybase.cma.ca/link/policy14450

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Return to school during COVID-19

https://policybase.cma.ca/link/policy14452

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)

Full policy recommendation:
1. The Canadian Medical Association encourages health services to review and assess interchangeability of COVID-19 vaccines, including the interchangeability of mRNA and viral vector vaccines. We recommend this assessment to be conducted by the manufacturer of the vaccine and shared with the public and health authorities.

Recommendation
1. The interchangeability of vaccines should be based on the manufacturer’s recommendation and the clinical context. This information should be shared with health care providers and the public.

Interchangeability of vaccines (vaccine mixing)

Interchangeability of vaccines

Interchangeability of vaccines is a concept that refers to the ability of different vaccines to be administered interchangeably. This concept is important in the context of the COVID-19 pandemic, as different vaccines may be available in different regions or countries. The interchangeability of vaccines is determined by the manufacturers and based on clinical trials and regulatory approvals.

Interchangeability of vaccines can be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different mechanisms, such as:

1. Direct interchangeability: This occurs when two vaccines are considered interchangeable and can be used as alternatives for each other. Direct interchangeability is usually determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Indirect interchangeability: This occurs when two vaccines are not considered interchangeable but can be used as alternatives for each other. Indirect interchangeability is determined by the manufacturers and is based on clinical trials and regulatory approvals.

Interchangeability of vaccines can also be achieved through different strategies, such as:

1. Sequential administration: This occurs when two vaccines are administered sequentially, with a certain period of time between administrations. Sequential administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.

2. Combination administration: This occurs when two vaccines are administered simultaneously, with a certain period of time between vaccinations. Combination administration is determined by the manufacturers and is based on clinical trials and regulatory approvals.
Firearms Control (Update 2021)
https://policybase.cma.ca/link/policy14401

POLICY TYPE
Policy document

DATE
2021-07-15

REPLACES
Firearms control (Update 2001)

TOPICS
Population health, health equity, public health
Health care and patient safety
Policy Brief: CSAM-SMCA in Support of the Decriminalization of Drug Use and Possession for Personal Use

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

The Canadian Interdisciplinary Palliative Care Competency Framework
CMA Policybase - Canadian Medical Association

p. 8
The Canadian Interdisciplinary Palliative Care Competency Framework
https://policybase.cma.ca/link/policy14439

POLICY TYPE
Policy endorsement

DATE
2020-12-05

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Committee Appearance – Justice and Human Rights: Bill C-7 – Amending the Criminal Code Regarding Medical Assistance in Dying
https://policybase.cma.ca/link/policy14374

POLICY TYPE
Parliamentary submission

DATE
2020-11-05

TOPICS
Health care and patient safety

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE       2020-08-13
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Pre-budget Submission
https://policybase.cma.ca/link/policy14259

POLICY TYPE
Parliamentary submission

DATE
2020-08-07

TOPICS
Physician practice, compensation, forms
Health information and e-health
Health care and patient safety
Health systems, system funding and performance

Documents
CMA Statement on Racism

https://policybase.cma.ca/link/policy14245

POLICY TYPE  
Policy document

DATE
2020-06-02

TOPICS  
Ethics and medical professionalism
Health care and patient safety

Documents
Responding to the COVID-19 pandemic: Federal measures to recognize the significant contributions of Canada’s front-line health care workers
https://policybase.cma.ca/link/policy14211

POLICY TYPE
Parliamentary submission

DATE
2020-05-28

TOPICS
Health care and patient safety

Documents
Framework for Ethical Decision Making During the Coronavirus Pandemic

https://policybase.cma.ca/link/policy14133

Policy document

DATE
2020-04-01

TOPICS
Ethics and medical professionalism
Health care and patient safety

Documents
Emergency federal measures to care for and protect Canadians during the COVID-19 pandemic

https://policybase.cma.ca/link/policy14132

**POLICY TYPE**  Parliamentary submission

**DATE**  2020-03-16

**TOPICS**  Health care and patient safety

---

CMA recommendations for EMERGENCY FEDERAL MEASURES TO CARE FOR AND PROTECT CANADIANS DURING THE COVID-19 PANDEMIC

Submitted to the Minister of Finance
March 16, 2020

---

**CMA Policybase - Canadian Medical Association**

---

CMA Policybase - Canadian Medical Association

p. 16
Authorizing Cannabis for Medical Purposes

CMA Policybase - Canadian Medical Association
Appropriateness in health care
https://policybase.cma.ca/link/policy11516

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2014-12-06
TOPICS  Health care and patient safety

Documents
Health Canada consultation on proposed vaping products promotion regulations
https://policybase.cma.ca/link/policy14128

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2020-01-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Health care and patient safety</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
Organ and tissue donation and transplantation
https://policybase.cma.ca/link/policy14126

POLICY TYPE
Policy document

DATE
2019-12-07

REPLACES
Organ and tissue donation and transplantation (update 2015)

TOPICS
Ethics and medical professionalism
Health care and patient safety

Documents